CD274 and neoplasm: Nivolumab plus ipilimumab was subsequently approved as the first-line treatment for patients with metastatic NSCLC, PD-L1 ≥ 1%, without EGFR or ALK genomic tumor aberrations by the United States (US) Food and Drug Administration (FDA) in May, 2020.